Cargando…

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases

Dear Editor, I am writing to you in order to highlight some miscalculations in an article published in the journal of Technology in Cancer Research & Treatment, entitled; “SRS in Combination with Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases” by Khan, et al.(1) The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badrigilan, Samireh, Choupani, Jalal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607808/ https://www.ncbi.nlm.nih.gov/pubmed/33111619 http://dx.doi.org/10.1177/1533033820965607

Ejemplares similares

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
por: Khan, Muhammad, et al.
Publicado: (2018)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

Assessment of imaging biomarkers in the follow-up of brain metastases after SRS
por: Derks, Sophie H A E, et al.
Publicado: (2021)

A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
por: Badrigilan, Samireh, et al.
Publicado: (2020)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
por: Minniti, Giuseppe, et al.
Publicado: (2019)

Ipilimumab in a Phase II trial of melanoma patients with brain metastases
por: Margolin, Kim
Publicado: (2012)

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
por: Wei, Guoqing, et al.
Publicado: (2012)

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
por: Ladányi, Andrea, et al.
Publicado: (2022)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases
por: Nguyen, Steven M, et al.
Publicado: (2017)

Diffusion weighted MRI is a promising imaging biomarker in brain metastases
por: Zakaria, R., et al.
Publicado: (2014)

Acral lentiginous melanoma with multiple brain metastases in an Indian male
por: Parimalam, Kumar, et al.
Publicado: (2016)

Metastases of malignant melanoma to stomach
por: Kuzu, Ufuk Barıs, et al.
Publicado: (2016)

Primary Regressive, But Metastasizing Melanoma!?
por: Tchernev, Georgi, et al.
Publicado: (2019)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Stereotactic radiosurgery (SRS) for brain metastases: a systematic review
por: Nieder, Carsten, et al.
Publicado: (2014)

Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases
por: Soliman, Hany, et al.
Publicado: (2016)

RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.
por: Harat, Maciej, et al.
Publicado: (2019)

Mixed Response to Ipilimumab in a Melanoma Patient with Brain Metastases: Case Report and Review of the Literature
por: Feldmann, Georg, et al.
Publicado: (2013)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Long-term Outcomes after Salvage Stereotactic Radiosurgery (SRS) following In-Field Failure of Initial SRS for Brain Metastases
por: Rana, Nitesh, et al.
Publicado: (2017)

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
por: Pham, Félix, et al.
Publicado: (2022)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Evaluation of Elements Spine SRS Plan Quality for SRS and SBRT Treatment of Spine Metastases
por: Trager, Michael, et al.
Publicado: (2020)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Cross Validity of the Korean Version of SRS-22 in Korean Patients with Idiopathic Scoliosis
por: Jeon, Kyoungkyu, et al.
Publicado: (2021)

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis
por: Bodensohn, Raphael, et al.
Publicado: (2023)

Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters
por: Schmidberger, Heinz, et al.
Publicado: (2018)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
por: Nguyen, Thuy Thi, et al.
Publicado: (2020)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2020)

Intracranial hemorrhagic metastases as the first manifestation of an occult melanoma
por: Reddy, V. Umamaheswara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h6kf6074ah29domsljilpc69bh